The role of biological therapy in inflammatory bowel disease

Drugs of Today

Volumn 37, Issue 2, 2001, Pages 121-133

  Su, C G ^a   Judge, T A ^a   Lichtenstein, G R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC THERAPY; BIOLOGICAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DERMATITIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEADACHE; HUMAN; IMMUNOMODULATION; PRURITUS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0035069864     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.2.614848     Document Type: Review

References (71)

1. Medical therapy for Crohn's disease: The state of the art
2. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment
3. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
4. Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease
5. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization
6. Soluble tumor necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment in inflammatory bowel disease
7. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
8. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
9. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
10. Targeting TNF α as a key cytokine in the inflammatory processes of Crohn's disease. - The mechanisms of action of infliximab
11. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease
12. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
13. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
14. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (α) for Crohn's disease. Crohn's Disease cA2 Study Group
15. Infliximab in Crohn's disease: First anniversary clinical experience
16. Clinical experience with infliximab therapy in 100 Crohn's disease patients
17. Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease
18. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
19. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
20. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
21. Infliximab for the treatment of fistulas in patients with Crohn's disease
22. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis
23. Infliximab is an effective therapeutic agent for ulcerative colitis
24. Treatment of severe esophageal Crohn's disease with infliximab
25. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctocolectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: Report of two cases
26. Successful management of Crohn's disease of the ileoanal pouch with infliximab
27. Treatment of fistulizing Crohn's disease
28. Review article: Safety of infliximab in clinical trials
29. Infliximab and inflammatory bowel disease: Current and future perspectives
30. The relationship between infliximab treatment and lymphoma in Crohn's disease
31. Randomized controlled trial of CDP571 anti-body to tumor necrosis factor-α in Crohn's disease
32. A controlled trial of anti-tumor necrosis factor α antibody for Crohn's disease
33. A randomized controlled trial of CDP571, a humanized antibody to TNFα, in moderately to severely active Crohn's disease
34. A randomized, double-blind, placebo, controlled multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
35. Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571
36. Etanercept (TNF receptor fusion protein, Enbrel®) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
37. New life in a sleeper: Thalidomide and Crohn's disease
38. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
39. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
40. Open labeled pilot study of thalidomide as a novel therapy for medically resistant ulcerative colitis
41. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroids dependent chronic active Crohn's disease
42. Interleukin-10-deficient mice develop chronic enterocolitis
43. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
44. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease
45. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STEMM-CD)
46. A safety and efficacy study of recombinant human interleukin-10 (rHulL-10) treatment in 329 patients with chronic active Crohn's disease
47. Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn's disease
48. Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn's disease
49. Safety and tolerance of rHulL-10 treatment in patients with mild/moderate active ulcerative colitis
50. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn's disease
51. CD40L is important for induction of, but not response to, costimulatory activity: ICAM-1 as the second costimulatory molecule rapidly upregulated by CD40L
52. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (slCAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis
53. Circulating soluble adhesion molecules in inflammatory bowel disease
54. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
55. Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent Crohn's disease
56. Anti-sense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease: Lack of efficacy in a prospective, double-blind, multicenter randomized trial
57. 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation
58. 4 integrin monoclonal antibody
59. 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45Rbhigh CD4+T cells
60. 7 antibody in ulcerative colitis
61. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease
62. Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (R-MethuG-CSF) in mucosal and fistulizing Crohn's disease
63. Safety and efficacy of granulocyte colony stimulating factor (G-CSF) for treatment of severe endoscopic post-operative recurrence in Crohn's disease
64. Response to heparin in patients with ulcerative colitis
65. Paradoxical response to heparin in 10 patients with ulcerative colitis
66. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases
67. Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease
68. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease
69. Comparison of heparin and steroids in the treatment of moderate to severe ulcerative colitis
70. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
71. A preliminary study of growth hormone therapy for Crohn's disease